76 completed, 14 terminated, 10 unknown, 7 withdrawn. 32 Phase 4, 23 Phase 2, 22 Phase 1, 21 Not applicable, 20 Phase 3.
Follow Lorazepam: new trials by email Literature Review of Lorazepam trials Research Report on Lorazepam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lorazepam for Delirium Prevention in Critically Ill Patients With High Anttila-Index Lorazepam 1 mg, Placebo - Delirium Confusional State | Phase 4 | Not yet recruiting | University Hospital, Basel, Switzerland | 260 | 2027-03-01 | 2026-02-27 |
| Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham - Major Depression | Early Phase 1 | Recruiting | Mclean Hospital | 80 | 2026-03-11 | 2026-05-13 |
| Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study Lorazepam 1 mg, Ibuprofen 800 mg - Pain, IUD | Phase 2 | Withdrawn | University of Wisconsin, Madison | 2025-10-01 | 2025-10-30 | |
| HPV Vaccine Reduced Dose Gardasil-9, Lidocaine injection, Lorazepam - HPV | Phase 4 | Recruiting | Emory University | 100 | 2025-08-06 | 2026-08-31 |
| Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia Methoxyflurane - Penthrox, Control, Percocet Pill - Benign Prostate Hypertrophy(BPH) | Phase 3 | Not yet recruiting | University of Manitoba | 48 | 2025-08-01 | 2025-06-12 |
| Computational Assessment of GABA Receptor Modulation in PTSD Lorazepam 1 mg tablet, Placebo tablet - Stress Disorders, Post-Traumatic | Phase 4 | Recruiting | VA Office of Research and Development | 150 | 2025-07-01 | 2026-06-16 |
| Acute Agitation in Emergency Psychiatry Sublingual Dexmedetomidine, Buccal midazolam, Oral lorazepam - Agitation | Phase 2 / Phase 3 | Recruiting | Lone Baandrup | 132 | 2024-12-30 | 2025-01-01 |
| Ketamine for Sedation in Severe Traumatic Brain Injury Ketamine with propofol, Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam - Severe Traumatic Brain Injury, Intracranial Hypertension | Phase 4 | Suspended | Henry M. Jackson Foundation for the Advancement of Military Medicine | 50 | 2024-09-23 | 2025-07-14 |
| A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems Mianserin, Lorazepam - Depression | Phase 4 | Unknown | Zhenghui YI | 300 | 2024-07-01 | 2024-06-27 |
| Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult Dexmedetomidine, Lorazepam, Haloperidol - Altered Mental Status | Phase 3 | Unknown | State University of New York - Upstate Medical University | 60 | 2024-06-01 | 2024-04-22 |
| Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg) - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 20 | 2024-02-01 | 2025-11-17 |
| Efficacy of Hydroxyzine for Patients With Panic Disorder Hydroxyzine, Escitalopram Oxalate - Panic Disorder | Phase 4 | Not yet recruiting | Sultan Qaboos University | 80 | 2023-12-30 | 2023-02-21 |
| Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression Lorazepam, Placebo - Depression, Anxiety, Fear | Phase 4 | Recruiting | Laureate Institute for Brain Research, Inc. | 165 | 2023-11-08 | 2025-10-31 |
| Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder Dexmedetomidine, Lorazepam 2 MG/ML - Schizophrenia Agitation, Schizo Affective Disorder | Phase 4 | Unknown | Temple University | 32 | 2023-07-01 | 2023-10-23 |
| Therapies for Down Syndrome Regression Disorder Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib - Down Syndrome, Regression | Phase 2 | Completed | University of Colorado, Denver | 66 | 2023-06-29 | 2026-09-03 |
| Lorazepam Effects on Neuroimaging Measures Lorazepam 1Mg Tablet, Placebo - Lorazepam, Neuroimaging | Early Phase 1 | Withdrawn | Northwell Health | 2022-01-01 | 2022-05-27 | |
| Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose IXT-m200, Lorazepam, Haloperidol - Methamphetamine Intoxication (Disorder) | Phase 2 | Terminated | InterveXion Therapeutics, LLC | 20 | 2021-06-30 | 2023-11-18 |
| Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity Carbamazepine, Lorazepam, Dextromethorphan - Low Intensity Focussed Ultrasound | Early Phase 1 | Active not recruiting | University Health Network, Toronto | 20 | 2021-05-25 | 2025-08-03 |
| Multimodal Analgesia Effect on Post Surgical Patient Neurontin, Dilaudid Injectable Product, Marcaine Injectable Product - Obesity, Morbid, Surgery | Phase 4 | Completed | University of California, Davis | 60 | 2021-01-20 | 2026-09-14 |
| Lorazepam for the Analgosedation of Pediatric Patients in Mechanical Ventilation. Lorazepam 4 mg/ml - Analgesia | Phase 2 | Unknown | Bambino Gesù Hospital and Research Institute | 9 | 2020-12-01 | 2020-11-27 |
Showing 20 of 120. Sign in to see all of them.
Anxiety Disorders (10) · Status Epilepticus (10) · Depression (6) · Seizures (6) · Delirium (5) · Epilepsy (5) · Psychomotor Agitation (5) · Schizophrenia (5) · Alcoholism (4) · Generalized Anxiety Disorder (4) · Pain (4) · Psychotic Disorders (4) · Agnosia (3) · Bipolar Disorder (3) · Depressive Disorder, Major (3)
Pfizer (6) · AstraZeneca (4) · GlaxoSmithKline (3) · Mayo Clinic (3) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (3) · Virginia Commonwealth University (3) · Emory University (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · M.D. Anderson Cancer Center (2) · Mclean Hospital (2) · National Cancer Institute (NCI) (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Orasi Medical, Inc. (2) · Stanford University (2) · University Hospital, Basel, Switzerland (2)
United States (69) · Canada (7) · Netherlands (7) · France (4) · Japan (3) · Spain (3) · Denmark (2) · Germany (2) · India (2) · Lithuania (2) · Puerto Rico (2) · Taiwan (2) · Argentina (1) · Austria (1) · Belgium (1)
Alice P Chen, M.D. (2) · Concetta Forchetti, MD, PhD (2) · James Chamberlain, MD (2) · Andrew Grigg, Professor (1) · Angela Christiano, PhD (1) · Angelina Kakooza-Mwesige, MMed (1) · Annemiek Vermeeren, Ph.D. (1) · Audis Bethea, PharmD, BCPS (1) · Barbara Jachniewicz, MSN, CRNFA, (1) · Barry Ruijter, MD (1) · Beth L Murphy, MD/PhD (1) · Bhagat Aulakh, MD (1) · Bradley Dengler, MD (1) · Brian E Cairns, PhD DrMed (1)
PMID 16785215, PMID 17196053, PMID 18073360, PMID 19573495, PMID 20233428, PMID 20887370, PMID 21040558, PMID 21275979, PMID 21967361, PMID 22144928, PMID 22335736, PMID 22506949, PMID 22898443, PMID 22950484, PMID 23090523, PMID 23635914, PMID 24001080, PMID 24035344, PMID 24351233, PMID 24462034, PMID 24756515, PMID 25372846, PMID 25734733, PMID 25791540, PMID 26315980, PMID 26384469, PMID 26710961, PMID 26971488, PMID 27022468, PMID 27282374, PMID 27993298, PMID 28781452, PMID 28975307, PMID 29024230, PMID 29238824, PMID 29363356, PMID 29671186, PMID 30135030, PMID 30138687, PMID 30797651, PMID 30821824, PMID 30877186, PMID 31418168, PMID 32029262, PMID 32297992, PMID 32416996, PMID 33692709, PMID 33728561, PMID 34238838, PMID 34546899
2017 (1), 2019 (1), 2023 (1), K23AA000222 (1), K23DA014291 (1), K24AA016555 (1), R01MH059142 (1), R01MH084068 (1), R01MH118634 (1), R01MH132565 (1), R01MH139697 (1), R21CA186000 (1), U01DA053043 (1), U01NS056975 (1), U10CA081920 (1)